When this event to happen ?
Make your bet.
PDLI with an excellent management team are working diligently to invest in pharmaceutical companies to increase future royalties. Just read the last 3 months press releases….
Mizuho Securities Reiterates Buy on Questcor Pharmaceuticals on Stock Price Weakness
Last update: 26/11/2013 4:47:27 pm
In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR).
In the report, Mizuho Securities USA noted, "In the wake of today's stock price weakness on short report that FTC will challenge Synacthen deal, we ascertained that QCOR hasn't received a formal FTC inquiry, and anything informal might just be in response to updated HSR guidelines. Even if FTC pursued a court challenge, could take 2+ years to decide, and most recent product case went in favor of acquirer even though products looked more similar than Acthar/Synacthen."
If I were SUDA bord member I would advice the board to merge SUDA with NVDL for rurther trading on the USA stock exchange to get more cover.
SUDA on a critical time at this stage !!!
Artimist is the key product ( for the near term ) to SUDA future success.
Each product on SUDA basket could create a $1 Billion company value if marketing to run successfully.
(Please see INSY)
Regarding NVDL,,, I believe the worst behind the company and her shareholders. $1 price value withing 24 -36 months.
Up up away $$$$$$$$$$$$$$$$$$$$$$$$$$$
HITK was bought out by AKRX.
AKRX is a $2.5 billion company value.
Hopefully Zolpimist to take more attention at AKRX.
Financing is welcome BUT on what price?
MSLP needs at least $70 -$80 million for their expansion!!!
Marker markers are bunch of sharks, they would buy the stocks on IPO at a deep discount.
$6.50 - $7.00 MSLP IPO pricing sound rational.
With 8.86 Million shares outstanding (+) 10 – 12 million shares on IPO we have to consider total shares +/- 20 million.
20 million shares times $6.5 -$7.00 = $130-140 million market value.
$ 1 Billion company value within 12 moths !!!
Do not short this stock, it could be "ugly" while run up.
Risk Vs. Reward do not worth shorting.
$1 profit Vs. $10 loss ?
2013 has been a year of change in the landscape for publicly traded antibiotic developers, driven by Cubist Pharmaceuticals' (CBST) high-profile acquisitions of competitors Trius (TSRX) and Optimer (OPTR) for a combined sum of nearly $1.6 billion ($704 million and $801 million, respectively). By no means were these small acquisitions: Cubist currently trades at a valuation of just over $4.5 billion. (Read more about the acquisitions and why we're bullish on Cubist, here).
Make you due diligence for not been surprosed ...
CBST's Cubist antibiotic drug with annual sells of $1,000,000.
Cubist twice days use while DRTX antibiotic for once a week.
I see many $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ coming to DRTX.
No doubt This baby should trade at $20 !
You have to see the all picture.
The company has to raise some $50 -100 milion for all their expantion.
Market makers would like to make at least 25% profit on their comitment.....
3 months after secondery you will see result of this secondery not before .
I'm ready to buy at $6-7 .
Money maker company with huge potential to become key player in the china babies nutrision market.
Management wisely investment in franch powder milk plant !!!
Won't be surprise to see the stock price at $50 withing 2 years.
Good Luck !